

SCHOTT PHARMA AG & CO. KGAA

ISIN: DE000A3ENQ51 WKN: A3ENQ5 Asset Class: Stock

Company



2024/10/18 17:35:25

Price

31.08

EUR

Difference



1.17%(0.36)



Contact Details

SCHOTT PHARMA AG & CO.
KGAA

Tel: +49-6131-66-0

- -

Fax: +

Hattenbergstrasse 10

Web:

<https://www.schott.com>

55122 Mainz

E-mail: -

Company Profile

SCHOTT Pharma AG & Co. KgaA engages in the provision of designing drug containment and drug delivery solutions. It operates through the Drug Containment Solutions and Drug Delivery Systems segments. The Drug Containment Solutions segment focuses on the products from the Core category that currently make up the largest part of the DCS product portfolio. The Drug Delivery Systems segment includes products that are characterized by improved product functionality and belong to the HVS product portfolio. It offers a wide range of advanced drug containment solutions and delivery systems for injectable drugs that supply to the pharmaceutical and biotechnology industries. The company was founded on May 10, 2022 and is headquartered in Mainz, Germany.

Financial figures, Fiscal year: from 01.10. to 30.09.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	468,338,000		554,516,000		302,157,000	
Common stock capital		150,615,000		681,907,000		448,897,000
Fixed assets	778,119,000		656,671,000		447,748,000	
Equity capital of a company		692,179,000		709,044,000		419,418,000
Cash and cash equivalents	24,357,000		28,795,000		27,859,000	
Accrued liabilities		28,335,000		32,285,000		42,429,000
Other assets	-		-		-	
Current liabilities		351,146,000		323,019,000		244,207,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		203,132,000		179,124,000		86,280,000
Different income		-		-		-
Other liabilities		66,153,000		40,015,000		19,879,000
Total assets	1,246,457,000	1,246,457,000	1,211,187,000	1,211,187,000	749,905,000	749,905,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	4,646	4,683	4,528
Equity ratio	55.67%	58.69%	56.12%
Debt-equity ratio	79.62%	70.40%	78.18%

Others

	2023	2022	2021
Tax Expense Rate	19.46%	22.33%	20.18%

SCHOTT PHARMA AG & CO. KGAA

ISIN: DE000A3ENQ51

WKN: A3ENQ5

Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	898,602,000	821,144,000	648,668,000
Net income	151,842,000	125,379,000	100,753,000
EBIT	175,769,000	145,588,000	110,472,000
Operating income before taxes	174,060,000	145,298,000	109,582,000
Cash Flow	181,652,000	182,123,000	134,888,000
Net interest income	-1,709,000	-290,000	-890,000
Research and development expenses	26,822,000	23,527,000	22,289,000
Income taxes	33,868,000	32,440,000	22,117,000
Result from investments in subsidiaries, associates and other	11,742,000	12,990,000	13,702,000
Revenues per employee	193,414	175,346	143,257

Board of Directors

Peter Goldschmidt	Chairman of Supervisory Board
Wolfgang Wienand	Member of Supervisory Board
Ann-Kristin Erkens	Member of Supervisory Board
Christine Wening	Member of Supervisory Board
Eva Kienle	Member of Supervisory Board
Mario Just	Member of Supervisory Board

Members of Management Board

Andreas Reisse	Chairman of Managing Board
Almuth Steinkühler	Member of Executive Committee